Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38147034 | 0.91 | CXCR2 (0.47) | CXCR2EPHX2PPARGPPARATRPV1 | |
| SCHEMBL23461807 | 0.91 | CXCR2 (0.47) | CXCR2EPHX2PPARGPPARATRPV1 | |
| SCHEMBL25548965 | 0.90 | CXCR2 (0.57) | CXCR2EPHX2PPARGMAPT | |
| SCHEMBL25549128 | 0.88 | CXCR2 (0.45) | CXCR2EPHX2PDE2AMEN1KMT2A | |
| SCHEMBL23460779 | 0.83 | CXCR2 (0.51) | CXCR2EPHX2PPARGPPARATRPV1 | |
| SCHEMBL23460777 | 0.83 | CXCR2 (0.51) | CXCR2EPHX2PPARGPPARATRPV1 | |
| SCHEMBL23461051 | 0.81 | CXCR2 (0.59) | CXCR2PPARGMAPT | |
| SCHEMBL38147033 | 0.81 | CXCR2 (0.59) | CXCR2PPARGMAPT | |
| SCHEMBL23460901 | 0.79 | CXCR2 (0.47) | CXCR2EPHX2PPARGPPARATRPV1 | |
| SCHEMBL38147035 | 0.79 | CXCR2 (0.47) | CXCR2EPHX2PDE2AMAPTNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885EPHX2 1774/4885PPARG 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.